CAC 40
8 040,36 +17,95 (+0,22 %) Euro Stoxx 50
4 936,85 +18,76 (+0,38 %) Dow Jones
38 239,98 +253,58 (+0,67 %) EUR/USD
1,0648 -0,0008 (-0,07 %) Gold future
2 315,10 -31,30 (-1,33 %) Bitcoin EUR
62 373,89 +56,58 (+0,09 %)
Amgen Inc. (AMG.F)
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 26 700
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Robert A. Bradway | Chairman, CEO & President | 6,32M | S.O. | 1963 |
| Mr. Peter H. Griffith | Executive VP & CFO | 2,88M | S.O. | 1959 |
| Mr. Esteban Santos | Executive Vice President of Operations | 2,82M | S.O. | 1968 |
| Dr. David M. Reese M.D. | Executive VP & Chief Technology Officer | 3,19M | S.O. | 1963 |
| Mr. Murdo Gordon | Executive Vice President of Global Commercial Operations | 3,04M | S.O. | 1967 |
| Mr. Matthew C. Busch | Chief Accounting Officer & VP of Finance | S.O. | S.O. | 1974 |
| Mr. Mike Zahigian | Senior VP & Chief Information Officer | S.O. | S.O. | S.O. |
| Dr. James E. Bradner M.D. | Executive VP of Research and Development & Chief Scientific Officer | S.O. | S.O. | 1972 |
| Justin G. Claeys | Vice President of Investor Relations | S.O. | S.O. | S.O. |
| Mr. Jonathan P. Graham | Executive VP, General Counsel & Secretary | 2,29M | S.O. | 1961 |
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Amgen Inc. en date du 1 avril 2024 est 2. Les scores principaux sont Audit : 2; Société : 8; Droits des actionnaires : 1; Compensation : 2.
